Heart Matters

Patients with transthyretin amyloid cardiomyopathy (ATTR-CM) often experience significant quality of life challenges that extend beyond cardiac symptoms, including reduced mobility, fatigue, mood changes, and loss of independence. Dr. Kevin Shah discusses practical, patient-centered strategies to identify functional limitations, support emotional well-being, engage caregivers, and align treatment goals with what matters most to these patients. Dr. Shah is an Advanced Heart Failure and Transplant Cardiologist at Long Beach Memorial Hospital, as well as an Associate Professor of Medicine at the University of California Irvine School of Medicine.

Hypertension is a key modifiable cardiovascular risk factor, but its prevalence, progression, and outcomes vary significantly across patient populations. In this program, Dr. Alexandria May and Dr. Keith Ferdinand discuss how social drivers of health, geography, access to care, and comorbid conditions can influence risk and outcomes. Tune in to find out how we can better address variation in hypertension across patient groups. Dr. Ferdinand is the Gerald S. Berenson Chair in Preventive Cardiology and the Director of Preventive Cardiology at Tulane University School of Medicine in New Orleans.

This episode is sponsored by Mineralys Therapeutics Inc. Medical Affairs.

Familial chylomicronemia syndrome (FCS) is a rare genetic disorder that can severely disrupt triglyceride metabolism and place patients at risk for life-threatening complications like acute pancreatitis. Tune in to hear Dr. Robert Eckel in conversation with Dr. Steve Jackson as they break down the key cardiometabolic risks of FCS and how emerging therapies are changing the outlook for patients living with this complex disease. Dr. Eckel is a Professor of Medicine Emeritus at the University of Colorado Anschutz Medical Campus, with appointments in endocrinology, metabolism and diabetes, and cardiology.

The field of sports cardiology has experienced remarkable growth, with new guidelines, expanding programs, and increasing recognition of cardiovascular risk in athletes. Hear from Dr. Jeffrey Hsu as he shares current and emerging approaches to risk assessment, prevention, and management of cardiac conditions in this population. Dr. Hsu is a Clinical Assistant Professor of Medicine at the David Geffen School of Medicine at UCLA, and he spoke about this topic at the 2026 American College of Cardiology (ACC) Scientific Sessions.

For patients newly diagnosed with transthyretin amyloid cardiomyopathy (ATTR-CM), it's essential to set realistic expectations and prioritize whole-person care. Dr. Joban Vaishnav, Assistant Professor of Medicine and Director of the Comprehensive Amyloidosis Center at Johns Hopkins Medicine, shares insights on guiding these patients through this diagnosis.

When transthyretin amyloid cardiomyopathy (ATTR-CM) progresses, an individualized and empathetic approach to patient conversations is key. Hear from Dr. Joban Vaishnav as she shares practical strategies for addressing patient fears while clarifying what progression truly means. Dr. Vaishnav is an Assistant Professor of Medicine and Director of the Comprehensive Amyloidosis Center at Johns Hopkins Medicine in Baltimore.

Artificial intelligence has rapidly advanced disease recognition in transthyretin amyloid cardiomyopathy (ATTR-CM), and its role in guiding treatment selection, predicting progression, and refining prognosis is now being explored. Discover what's next in ATTR-CM care with Dr. Frederick Ruberg, Chief of Cardiovascular Medicine at Boston Medical Center and Thomas J. Ryan Professor of Cardiovascular Medicine at Boston University Chobanian & Avedisian School of Medicine.

The Masterclass in Cardiac Amyloidosis, 4-virtual 2.5 hr sessions, is focused on sharpening clinical skills in suspecting, diagnosing, treating, and longitudinally managing patients with ATTR cardiac amyloidosis.

ASNC will offer a focused 2-hour session for technologists titled, Amyloidosis for Technologists: Tips and Tricks from Experts on Saturday, March 14 from 1-3pm ET.

New therapeutic approaches are reshaping how we think about managing transthyretin amyloidosis (ATTR). Gain insight into the next generation of ATTR therapies as Dr. Ahmad Masri highlights evolving strategies beyond traditional stabilizers. He's an Associate Professor of Medicine in the Division of Cardiovascular Medicine at Oregon Health and Science University.

In the past decade, significant strides have been made in diagnosing and treating patients with transthyretin amyloid cardiomyopathy (ATTR-CM). Increased disease awareness, non-invasive diagnostic tools like scintigraphy, and AI-assisted screening have led to earlier detection and improved outcomes. Learn more with Dr. Kevin Alexander, an Assistant Professor of Cardiovascular Medicine at the Stanford University School of Medicine.